NovaDigm Therapeutics, Inc.
NovaDigm is developing innovative immunotherapeutics and preventative vaccines to protect patients from fungal and bacterial disease, which can be recurrent, drug-resistant and in some cases, life-threatening. NovaDigm’s lead development candidate, NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, including nosocomial candidiasis, a severe life threatening infection and Staphylococcus aureus, including MRSA.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Nationally (across the country)
About Us
NovaDigm is developing innovative immunotherapeutics and preventative vaccines to protect patients from fungal and bacterial disease, which can be recurrent, drug-resistant and in some cases, life-threatening. NovaDigm’s lead development candidate, NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. A Phase 2 efficacy study of NDV-3A versus placebo in patients with recurrent vulvovaginal candidiasis (RVVC) demonstrated that a single dose of NDV-3A resulted in an increase in the recurrence-free rate out to 12 months and extended the time to first recurrence for those that had a recurrence. Clinical development has also begun to assess the potential impact of NDV-3A in the prevention of S. aureus skin and soft tissue infections. The Company’s founding scientists from the Los Angeles Biomedical Research Institute (LA BioMed) at Harbor-UCLA Medical Center are recognized leaders in the field of infectious disease and the emerging threat of “superbugs.” NovaDigm has received funding from Domain Associates and RMI Partners and collaborates with multiple government agencies.
